cp094 has been researched along with aminolevulinic acid in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 4 (50.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bown, SG; Chang, SC; MacRobert, AJ; Porter, JB | 1 |
| Bech, O; MacRobert, AJ; Moan, J; Phillips, D | 1 |
| Bown, SG; Curnow, A; MacRobert, AJ | 1 |
| Curnow, A; Pye, A | 1 |
| Campbell, S; Curnow, A; Pye, A | 1 |
| Alyahya, R; Campbell, SM; Curnow, A; Horton, S; Morton, CA; Pye, A | 1 |
| Curnow, A; Dodd, NJF; Dogra, Y; Ferguson, DCJ; Smerdon, GR; Winyard, PG | 1 |
| Curnow, A; Perry, A; Wood, M | 1 |
2 trial(s) available for cp094 and aminolevulinic acid
| Article | Year |
|---|---|
Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Topics: Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Cell Line, Tumor; Humans; In Vitro Techniques; Iron Chelating Agents; Middle Aged; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Protoporphyrins; Pyridones; Skin Neoplasms | 2008 |
Clinical investigation of the novel iron-chelating agent, CP94, to enhance topical photodynamic therapy of nodular basal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Aminolevulinic Acid; Carcinoma, Basal Cell; Dose-Response Relationship, Drug; Female; Humans; Iron Chelating Agents; Male; Middle Aged; Pain; Photochemotherapy; Photosensitizing Agents; Pilot Projects; Pyridones; Skin Neoplasms; Treatment Outcome | 2008 |
6 other study(ies) available for cp094 and aminolevulinic acid
| Article | Year |
|---|---|
The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.
Topics: Administration, Intravesical; Aminolevulinic Acid; Animals; Female; Iron Chelating Agents; Kinetics; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Pyridones; Rats; Rats, Wistar; Spectrometry, Fluorescence; Urinary Bladder | 1997 |
A hydroxypyridinone (CP94) enhances protoporphyrin IX formation in 5-aminolaevulinic acid treated cells.
Topics: Aminolevulinic Acid; Cell Line; Darkness; Humans; Iron Chelating Agents; Microscopy, Fluorescence; Molecular Structure; Prodrugs; Protoporphyrins; Pyridones; Spectrometry, Fluorescence | 1997 |
Comparing and combining light dose fractionation and iron chelation to enhance experimental photodynamic therapy with aminolevulinic acid.
Topics: Aminolevulinic Acid; Animals; Colon; Colonic Neoplasms; Dose Fractionation, Radiation; Female; Fibrosarcoma; Iron Chelating Agents; Photochemotherapy; Photosensitizing Agents; Pyridones; Rats; Rats, Wistar | 2006 |
Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.
Topics: Aminolevulinic Acid; Carcinoma, Squamous Cell; Cell Line, Tumor; Deferoxamine; Dose-Response Relationship, Drug; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; Esters; Fibroblasts; Fluorescence; Humans; Iron Chelating Agents; Lung; Microscopy, Fluorescence; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Pyridones | 2007 |
The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Histidine; Humans; Iron Chelating Agents; Metalloporphyrins; Photochemotherapy; Photosensitizing Agents; Protoporphyrins; Pyridones; Reactive Oxygen Species | 2016 |
Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
Topics: Aminolevulinic Acid; Cell Line, Tumor; Cell Survival; Humans; Iron Chelating Agents; Photochemotherapy; Photosensitizing Agents; Prodrugs; Protoporphyrins; Pyridones; Skin Neoplasms | 2019 |